Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00147654
First received: September 2, 2005
Last updated: June 7, 2011
Last verified: June 2011

September 2, 2005
June 7, 2011
November 2004
Not Provided
  • Patient Perception of Treatment Benefit at Week 12:
  • Treatment benefit, treatment satisfaction, and willingness to continue treatment questions at week 12
  • Treatment benefit, treatment satisfaction, and willingness to continue treatment questions at week 12
  • Patient Perception of Treatment Benefit at Week 12:
Complete list of historical versions of study NCT00147654 on ClinicalTrials.gov Archive Site
  • Micturition Diary- Change in number of urge incontinence episodes per 24 hours at week 1, week 6 and 12 relative to baseline.
  • Change in number of urge episodes per 24 hours at week 1, week 6 and 12 relative to baseline.
  • Change in number of micturitions per 24 hours at week 1, week 6 and 12 relative to baseline.
  • Change in number of daytime micturitions per 24 hours at week 1, week 6 and 12 relative to baseline
  • Change in number of nighttime micturitions per 24 hours at week 1, week 6 and 12 relative to baseline
  • Change in the average severity of the Urinary Sensation Scale at week 1, week 6, and week 12 relative to baseline
  • Change in number of OAB micturition episodes per 24 hours (OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score 3) at week 1, week 6 and week 12 relative to baseline
  • Change in number of daytime OAB micturition episodes per 24 hours (OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score 3) at week 1, week 6 and week 12 relative to baseline
  • Change in number of nighttime OAB micturition episodes per 24 hours. (severe OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score 4) at week 1, week 6 and week 12 relative to baseline
  • Change in number of severe OAB micturition episodes per 24 hours (severe OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score 4) at week 1, week 6 and week 12 relative to baseline
  • Change in number of daytime severe OAB micturition episodes per 24 hours (severe OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score 4) at week 1, week 6 and week 12 relative to baseline
  • Change in number of nighttime severe OAB micturition episodes per 24 hours (severe OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score 4) at week 1, week 6 and week 12 relative to baseline
  • International Prostate Symptom Score (I-PSS):
  • Change in I-PSS total score at weeks 1, 6 and 12 relative to baseline
  • Change in I-PSS individual item scores (Q1, Q2, Q3, Q4, Q5, Q6, and Q7) at weeks 1, 6 and 12 relative to baseline
  • Change in I-PSS irritative domain (Sum of Q2, Q4, and Q7) at weeks 1, 6 and 12 relative to baseline
  • Change in I-PSS obstructive domain (Sum of Q1, Q3, Q5, and Q6) at weeks 1, 6 and 12 relative to baseline
  • Change in I-PSS index score (Sum Q1 to Q7) at weeks 1, 6 and 12 relative to baseline
  • Change in I-PSS QoL score (Q8) at weeks 1, 6 and 12 relative to baseline
  • Patient perception of urgency:
  • Change in the Perception of Urgency Scale (3 point scale) at week 1, week 6 and week 12 relative to baseline
  • Change in Patient's Perception of Bladder Condition at week 1, week 6 and week 12 relative to baseline
  • Patient Perception of Treatment benefit at week 1 and week 6
  • Treatment benefit and treatment satisfaction questions will be completed at week 1 and week 6
  • Change in International Continence Society Male (ICSmaleLF) Questionnaire (long form modified) individual item scores at Week 1, Week 6 and Week 12 relative to baseline
  • Change in the total score of Overactive Bladder Questionnaire (OABq) and change in total scores for each domain of OABq at week 6 and week 12 relative to baseline
  • Change in the total score of International Index of Erectile Function (IIEF) and change in total scores for each domain of IIEF Questionnaire at week 6 and week 12 relative to baseline
  • Information was omitted due to their commercial sensitivity, and will be revealed at a later date
  • Micturition Diary:
  • Change in number of urge incontinence episodes per 24 hours at week 1, week 6 and 12 relative to baseline
Not Provided
Not Provided
 
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin) Study To Evaluate The Clinical Efficacy And Safety Of Tolterodine ER 4 mg In Men Who Have Frequency and Urgency, With Or Without Urinary Urge Incontinence, With Or Without Bladder Outlet Obstruction

The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge incontinence (UUI), with or without bladder outlet obstruction (BOO).

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Urinary Incontinence
  • Drug: Tolterodine ER 4 mg QD
  • Drug: Tamsulosin 0.4 mg QD
Not Provided
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006 Nov 15;296(19):2319-28. Erratum in: JAMA. 2007 Mar 21:297(11):1195.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
830
May 2006
Not Provided

Inclusion Criteria:

  • Male 40 years of age
  • Clinical signs and symptoms of frequency and urgency, with or without UUI, with or without BOO, for at least three months
  • Mean urinary frequency of 8 micturitions/24h verified by the Screening micturition diary

Exclusion Criteria:

  • Post-void residual urine volume (PVR) of > 200 ml as measured by an ultrasound
  • Maximum urinary flow rate (Qmax) of < 5 ml/second as measured by a flowmeter; a voided volume of 75 ml is required in order to accurately record the Qmax
  • Prescribed and administered an antimuscarinic or antispasmodic within 1 month
  • Prescribed and administered an a-1-adrenergic antagonist within 2 weeks
Male
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00147654
A6121120
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP